Dr. Mercola Interviews Dr. Malcolm Kendrick on Statins

Mercola Videos

A 2015 systematic review of statin trials found that in primary prevention trials, the median postponement of death was just 3.2 days. In secondary prevention trials, death was postponed 4.1 days.
A 2018 review presents substantial evidence that total cholesterol and LDL cholesterol levels are not an indication of heart disease risk, and that statin treatment is of “doubtful benefit” as a form of primary prevention for this reason.
Tactics used in statin studies to exaggerate benefits include excluding unsuccessful trials, cherry-picking data, ignoring the most important outcome — an increase in life expectancy — and using a statistical tool called relative risk reduction to amplify trivial effects.
If you look at absolute risk, statin drugs benefit just 1% of the treated participants. Out of 100 people treated with statins for five years, one person will have one less heart attack.
Statin trials minimize health risks by using a run-in period. Participants are given the drug for a few weeks, after which those who suffer adverse effects are simply excluded, thereby lowering the perceived frequency and severity of side effects. Subscribe for the latest health news: http://bit.ly/2CEBM8j Visit our website: http://bit.ly/2KhnpuS Listen to our podcasts: http://bit.ly/34XeLcW Find us on Social Media
Facebook: https://www.facebook.com/doctor.health
MeWe: https://mewe.com/p-front/dr.josephmercola
Instagram: https://www.instagram.com/drmercola
Twitter: https://twitter.com/mercola Les artikkelen direkte fra kilden